Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002016
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase III Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody SDZ MSL-109 in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
Sponsor:
Sandoz
Organization:
NIH AIDS Clinical Trials Information Service